Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LCAR: SEC registration revoked.
https://www.sec.gov/litigation/opinions/2023/34-97070.pdf
LCAR: SEC Admin. Proceeding for severely delinquent Financials:
https://www.sec.gov/litigation/admin/2022/34-95536.pdf
Glenmede Trust Co becomes a shareholder owning 90k shares. Why would they purchase shares 30.9.2017 knowing the company is way behind in its reporting. Something is definitely up and cooking.
Where is all the volume coming from? Are we done yet or just getting started?
$LCAR: Starting to like the setup here
Have to agree with others here.... this looks like it wanna shimmy & Shake much higher from here.
$LCAR
$0.035
LCAR 10K and 10Q should be out soon. We have not had any trading activity lately. Any thoughts on that? Also noticed that their are out of their flagship product CATRIX OINTMENT on their website selling to general public. Worried about the product shortages, hope they can satisfy the demand. Anyone knows anything in works?
Hi, this seems to be news from 2006. Does anyone have some prove Lescarden inc is talking to big pharma?
Would love to get in and help promote the amazing company and opportunities
"The acquisition by Smith and Nephew was the next logical step for the company, very happy.."
For the nine months ended February 28, 2017 compared to February 28, 2016 revenues increased by 270%
LCAR going to be a biotech BEAST!!!!
LCAR already working in Spain with Smith and Nephew!
WOUND CARE now hottest biotech buyout sector, LCAR has CATRIX in demand!
LCAR to be purchased by British BIG PHARMA Smith and Nephew
Sales increased over 270 over last year would have been higher had production companies had more product available!
New big pharma partnership announcement coming for production consistency
EU also approved wound care product
FDA approved wound care product generating good sales!
Nice small share structure only 63M O/S
Thanks, got out as fast as I got in!!
Multi site pump/promo. Good for anyone that was in prior to open or bought the nominal amounts available prior to hitting .02 within the first minute or so of trading...
otc rockstar paid promo
Added a little LCAR today. I took it off my sleeper board because of the one-day promo. There's I'm sure some people here that consider themselves bagholders but the 10q will come out this week and should be excellent. Hang in there.
LCAR - Some Catrix products now available at Amazon
http://www.amazon.com/gp/search/ref=sr_nr_seeall_2?rh=k%3Acatrix%2Ci%3Ahpc&keywords=catrix&ie=UTF8&qid=1358791945
For the other 5 followers :)
LCAR - 10q filed last week shows revenues up 1,300% to over $1/4 million for three months. 10q also shows this was not a one shot deal; they have over $250,000 in accounts receivable and over $210,000 in inventory (which should become over $600,000 in revenues). I'm anticipating sales to grow from these levels, and the last time they had $1,000,000 in annual revenues the share price was .40. I'm very comfortable holding this.
LCAR - From 10q filed 1/11/13:
"The Company’s revenues increased in the fiscal quarter ended November 30, 2012 compared to November 30, 2011 by 1,300% or $250,377 due to the resumption of production operations at the Company’s sole raw material supplier and the fulfillment of outstanding purchase orders to European distributors"
LCAR seller gone for now. Almost exactly 150,000 shares traded with NITE on the ask every day at around .04 since 11/23. NITE at .40 now
LCAR mentioned in this report. Don't think I'll pay $4,950 to read it though :)
http://www.researchandmarkets.com/research/85zhqj/chitin_and
LCAR someone is accumulating .04s lately
Nice $1,500 buy yesterday at .03. Wasn't me, already in, holding with patience
Some older info concerning one of LCAR's products. Just dreaming here, maybe there's some developments requiring the need for all that new inventory they're getting :)
http://www.catrix.com
"A phase II study of Catrix-S in solid tumors.
Romano CF, Lipton A, Harvey HA, Simmonds MA, Romano PJ, Imboden SL.
Catrix-S is an acidic mucopolysaccharide complex derived from bovine tracheal cartilage. This material was administered by weekly subcutaneous injection (5.0-7.5 g/week) to nine patients with progressive metastatic malignancy. One complete response was seen in a patient with metastatic renal cell carcinoma to the lungs. Eight patients had progression of their disease. No undue toxicity and no consistent immunologic alteration was noted."
http://www.ncbi.nlm.nih.gov/pubmed/3878861
"Catrix: an easy-to-use collagen treatment for wound healing.
Collagen plays a major role in wound healing. Its presence is important in all stages of the healing process. Catrix is a new collagen wound-healing powder that has been shown to be effective in the treatment of wounds healing by secondary intent such as pressure ulcers, venous stasis ulcers and diabetic ulcers as well as second-degree burns and post-radiation dermatitis. Catrix has also been shown to be effective in the treatment of wounds unresponsive to conventional treatments. It promotes the growth of fibroblasts and keratinocytes in the wound, prevents loss of fluid from the wound and protects the wound from bacterial infections and other agents. Catrix is biodegradable and therefore does not require removal from the wound bed before re-application."
http://www.ncbi.nlm.nih.gov/pubmed/16245393
Based on their recent history LCAR is, imo, fairly valued now at .03. Now that their supply problems have been corrected I expect, within a few months, a return to their condition of a few years ago when they were worth .15. Their products:
http://www.catrix.com/home/index.htm
My interest in LCAR does not stem from now or the past but the future. Specifically, the chairman of the board paying $200,000 (via the purchase of common shares) specifically for the company's purchase of inventory. This is very, very friendly financing, as opposed to a promissory note, convertible debenture, or other possibly toxic financing from outsiders (Mr. Maxwell now owns over 60% of the outstanding stock). Why would a company need to more than triple their inventory level unless they were anticipating a robust growth in sales?
Reading their 10k filings from the last few years shows the promise that their products may provide, based on their own and other independent studies and trials. They have had limited success with market penetration but have a good base of repeat customers, mostly physicians in Asia.
Revenue growth could be coming from many sources. But there's a chance that new things could happen, specifically (from a 2010 study):
"The following have been reported from preclinical studies of the effect of powdered cartilage on cancer cells in vitro (outside of the body):
•In a published laboratory study, a powdered form of bovine cartilage called Catrix slowed the growth of human cancer cells by half or more. It is not clear if Catrix had this effect only on cancer cells, because its effect the growth of normal cells was not tested. It is also not known if the dose used in the laboratory study could safely be used in people."
http://www.cancer.gov/cancertopics/pdq/cam/cartilage/patient/page2
Success with their products in the field of cancer treatment would certainly be a game-changer for them. I consider that a pipe dream until I see further proof, but based on the company being, imo, "real," I'm willing to sit and wait on it. Meanwhile I do expect significant growth in sales of their regular products to be reported in the next 10q (Jan 2013).
Other reasons I like LCAR
Never been promoted
No toxic financing
No bagholders
what kind of value/pps does LCAR have iyo
LCAR 10Q out this week. Not much new in it but here's some tidbits from SEC filings in the last few months that lead me to believe there will be solid improvement in their revenues in the near future, specifically the purchasing of $200,000 worth of inventory, a huge increase from recent inventory levels.
"Raw material production delays and regulatory recertification of packaging facilities have resulted in order fulfillment lead times of greater than six months. Ongoing supply and production disruptions prevented fulfillment of $100,000 of customer purchase orders for the quarter ended August 31, 2012. The results of operations for the interim periods are not necessarily indicative of results to be expected for a full year's operations..."
"completion of the regulatory recertification of the Company’s packaging facility"
"We plan to add human resources and decrease reliance on outside sources of expertise as the Company returns to profitability."
"Pursuant to the Stock Purchase Agreement, the Company will issue a number of shares of common stock to the majority shareholder and Chairman of the Board equal $200,000 divided by average closing market price of the Company’s common stock during the three weeks preceding the date of the closing, or $0.023133 per share. Upon issuance, Maxwell will receive 8,645,533 shares of common stock resulting in a beneficial ownership of 30,512,378 shares, or 62.63%.
The proceeds from the issuance of stock are to be used for the purchase of inventory."
"The Company has no material commitments for capital expenditures at August 31, 2012."
From the LCAR 8k filed 9/26/12:
"Pursuant to the Stock Purchase Agreement, the Company will issue a number of shares of common stock to the majority shareholder and Chairman of the Board equal $200,000 divided by average closing market price of the Company’s common stock during the three weeks preceding the date of the closing, or $0.023133 per share. Upon issuance, Maxwell will receive 8,645,533 shares of common stock resulting in a beneficial ownership of 30,512,378 shares, or 62.63%. The proceeds from the issuance of stock are to be used for the purchase of inventory."
I find this interesting for 2 reasons:
1. No "toxic financing," insiders are financing inventory on a favorable basis and, imo, wouldn't do so unless a large increase in inventory was needed to support future sales growth.
2. $200,000 added to the current inventory level raises it to above where it was in 2008, when revenue was much higher than today's, and LCAR was trading at .15.
So, in my humble opinion, things are looking up for LCAR. But definitely a patience play, a rare buy and hold.
Next 10q should come out soon
Good to see LCAR doesn't need to pursue "toxic" financing. Insiders still have faith in the company's prospects. From 8k filed 9/26/12:
"Pursuant to the Stock Purchase Agreement, the Company will issue a number of shares of common stock to the majority shareholder and Chairman of the Board equal $200,000 divided by average closing market price of the Company’s common stock during the three weeks preceding the date of the closing, or $0.023133 per share. Upon issuance, Maxwell will receive 8,645,533 shares of common stock resulting in a beneficial ownership of 30,512,378 shares, or 62.63%.
The following sets forth the information required by Item 701 of Regulation S-K with respect to the unregistered sale of equity securities the Company completed on September 24, 2012:
? Effective August 10, 2012, the Company entered into a Stock Purchase Agreement with Maxwell pursuant to which Maxwell agreed to purchase, and the Company agreed to sell and issue 8,645,533 shares of common stock, $.001 par value for an aggregate purchase price of $200,000. The shares issued pursuant to the Stock Purchase Agreement were issued exclusively to one person who qualified as an "accredited investor" within the meaning of Rule 501(a) of Regulation D under the Securities Act of 1933 as amended (the "Securities Act"). The shares issued are “restricted securities” under the Securities Act.
? The Company paid no fees or commissions in connection with the issuance of the Shares.The sale of the Securities was undertaken without registration under the Securities Act in reliance upon an exemption from the registration requirements of the Securities Act set forth in Section 4(2) there under. The investor qualified as an "accredited investor" within the meaning of Rule 501(a) of Regulation D. The Company did not engage in any public advertising or general solicitation in connection with this transaction, and the investor was provided with disclosure of all aspects of the Company’s business, including reports filed with the Securities and Exchange Commission and other financial, business and corporate information.
? The proceeds from the issuance of stock are to be used for the purchase of inventory."
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
82
|
Created
|
04/13/10
|
Type
|
Free
|
Moderators |
Lescarden Inc. (LCAR)
Lescarden Inc/Catrix® is a biotechnology company dedicated to the development of natural, biologic therapies for burn and chronic wound management, clinical skin care, osteoarthritis and immune system applications.
Soon to be the #1 Penny Stock in America
Lescarden (LCAR) is a small biotech company that is a leader in the $17 BILLION Wound Care sector. Their lead product, Catrix is patented and has been approved by the EU and the FDA to treat chronic wounds, severe burns and multiple other applications!
Clinical and laboratory studies also point to Catrix as a potential agent for the treatment of certain cancers!
Lescarden (LCAR) is now believed to be in buyout discussions with British based BIG PHARMA Smith and Nephew who have operations in over 100 countries!
Smith and Nephew is one of the leading BIG PHARMA's investing in acquiring small Wound Care biotechs, and have already signed a licensing agreement with Lescarden (LCAR) for the distribution of Catrix in the Spain!
Lescarden (LCAR) also has signed an exclusive license agreement with Daewoong Pharmaceuticals, headquartered in Seoul, South Korea. Daewoong is the largest producer and marketer of over-the counter and ethical pharmaceutical products in Korea, with annual sales over $400 million. Already established in the diabetic foot ulcer segment of the market, Daewoong is expanding its product line to cover all aspects of wound treatment. This brings added value to any acquisition discussions with Smith and Nephew who would then increase their footprint in Asia!
Right now the hottest merger and acquisition sector in the biotech industry is Wound Care and the buyout rate of small biotech companies specializing in Wound Care is forecast to increase in 2017. The global market for Wound Care is projected to top $20 BILLION by 2021!
Lescarden (LCAR) already has a huge edge over many competitors, it has gone from FDA and EU approval to commercializing Catrix and has begun to set record revenues.
For the nine months ended February 28, 2017 compared to February 28, 2016 revenues increased by 270% approaching half a million dollars. Sales would have been even higher but supply issues led to the delayed shipment of Catrix to Smith and Nephew!
Lescarden (LCAR), trading at 2 cents a share is going to get snapped up! Just read below all the buyouts and acquisitions that have been occurring in the previously overlooked wound care sector!
LCAR's Catrix is an amazing product, when applied directly to non-healing wounds, such as debubitus ulcers (bedsores), diabetic ulcers, and venous ulcers, Catrix Wound Dressing actually accelerates the healing process, effectively closing the wounds while minimizing scarring.
In studies performed on wounds that had previously failed to respond to months of standard wound healing treatment, dramatic improvements were seen in just seven weeks!
BUT IT GETS EVEN BETTER
Clinical and laboratory studies also point to Catrix as a potential agent for the treatment of certain cancers!
Lescarden (LCAR) also has 2 other products that have been commercialized:
-Poly-NAG in the anti-arthritic market as a treatment for osteoarthritis. Clinical trials were so successful that both the US and EU awarded patents to Lescarden (LCAR)! This is a huge market with North American sales of anti-arthritic remedies are over $400 million annually.
-Bio-Cartilage, a pure Bovine Tracheal Cartilage supplement used for the potential treatment for certain types of cancer, Inflammatory Joint Disease and as a immune system enhancer.
Lescarden (LCAR) is EXTREMELY UNDERVALUED, trading near historic lows around 2 cents a share and UNDER THE RADAR!
Now is the time to BUY shares of Lescarden (LCAR)
LCAR has a tiny share structure with only 63M O/S of which INSIDERS own 22M, the float is a mere 16M shares.
(This means that the share price could rise very quickly with limited shares available!)
WOUND CARE is now HUGE business for pharmaceutical companies!
What makes Lescarden Inc. (LCAR) so attractive is that big pharmaceutical companies have until recently overlooked the wound care market. In the last few years a spate of buyouts and acquisitions has begun as BIG PHARMAS start to scoop up smaller players.
NOW is the time to buy shares of tiny LCAR, they will be acquired by the end of 2017!
JUST LOOK AT THESES HEADLINE CLIPS:
Overlooked Advanced Wound Care Market Catches Attention of Healthcare Analysts, Investors
Predictably, several healthcare analysts and some savvy investors have started paying attention to this niche market.
There are about 50 million reported cases globally of patients suffering from hard-to-close wounds, according to published reports, including some 15% of diabetic foot ulcers in the U.S. that eventually required amputations are creating a compelling product offering for healthcare professionals treating the 900,000 diabetic foot ulcers each year!
Wound Care Is "Big Business" Both large pharmaceutical companies and device companies have realized that wound care is big business, For example, wound bandages and dressings are a $2 billion business in the USA, he said. Smith & Nephew and Johnson & Johnson have been among the first major pharmaceutical companies to recognise the potential of the wound care market
The global wound care market is expected to reach USD 20.4 Billion by 2021 from USD 17.0 Billion in 2016, growing at a CAGR of 3.6% from 2016 to 2021.
The advanced wound management product segment commanded the largest share in 2015, and is forecast to be the fastest-growing segment in the wound care market. Factors such as rising awareness regarding new technologies for wound care, government support in the form of funding, and rising diabetic and aging population are driving the growth of the wound care market.
The prominent players in the wound care market are 3M Company (U.S.), Baxter International, Inc. (U.S.), Coloplast A/S (Denmark.), Convatec Healthcare B.S.A.R.L (U.S.), Covidien PLC (Ireland), Derma Sciences, Inc. (U.S.), Ethicon, Inc. (U.S.), Hollister, Inc. (U.S.), Kinetic Concept, Inc. (U.S.), Mölnlycke Health Care (Sweden), and Smith & Nephew (U.K.).
MORE ABOUT Lescarden Inc. (LCAR)
Lescarden Incorporated is a biotechnology company dedicated to the research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, autoimmune and cancer applications!
Years of product testing and refinement has led to the creation of Lescarden’s proprietary formula for purifying bovine cartilage producing a sterile white powder that optimizes the healing and anti-inflammatory processes. Today, the company’s exclusive bovine cartilage powder, marketed as Catrix®, is FDA and EU approved for the management of chronic wounds and severe burns.
Clinical and laboratory studies point to Catrix as a potential agent for the treatment of certain cancers.
The cornerstone of the Catrix product line, Catrix Wound Dressing is renowned for its superior healing characteristics.
Catrix Wound Dressing is a natural, biodegradable product, made from a specially processed bovine cartilage in the form of a fine white powder. Catrix has no chemical additives.
When applied directly to non-healing wounds, such as debubitus ulcers (bedsores), diabetic ulcers, and venous ulcers, Catrix Wound Dressing actually accelerates the healing process, effectively closing the wounds while minimizing scarring.
In studies performed on wounds that had previously failed to respond to months of standard wound healing treatment, dramatic improvements were seen in just seven weeks!
FDA-cleared for multiple healing applications
Catrix Wound Dressing is cleared for use by the Food and Drug Administration and is EU-certified for the management of:
Pressure ulcers (stages I-IV)
Stasis ulcers
1st and 2nd degree burns
Diabetic ulcers
Post-surgical incisions
Radiation dermatitis
Cuts, abrasions and irritations
Partial thickness wounds
Skin conditions associated with peristomal care
How Catrix Wound Dressing works
The unique properties Catrix Wound Dressing work with the body’s own healing capabilities to effectively close wounds. Catrix stimulates granulation within the wound, establishing a matrix that induces the development of the necessary components (connective tissue, skin, blood vessels) needed to heal. Containing 50% micronized collagen, Catrix Wound Dressing accelerates the biological process of reparation by activating the following processes:
Attracts fibroblasts – encourages production of connective tissue
Activates macrophages – stimulates formation of blood vessels
Stimulates growth of fibroblastes (12%) and keratinocytes (40%)
Stimulates growth fibroblasts and keratinocytes
Increases scar strength (resistance of the wound to tearing) by 50%
The result is a wound that heals rapidly, displays better quality of granulation and vascularization tissue, and a scar that is more aesthetic with superior tensile strength at every stage of its
subsequent recovery.
Advantages of Catrix Wound Dressing
Biodegradable - does not need to be removed from the wound
Completely absorbed at seven days
Compatible with gauzes and with moist applications
Can absorb exudate up to 10 times its weight
Controls excess exudates. Keeps the bed of the wound moist
Has a barrier effect – protects against infection
Does not harm the skin around the ulcer
Application is painless
Reduces bleeding
Has no adverse effects
Good for patients and the healthcare system
Catrix Wound Dressing offers important benefits to patients and healthcare providers:
Accelerated healing of wounds - leads to increased patient comfort, improved quality of life, and reduced chance of accidental infection
Decreased treatment cost - dramatic savings through reduced staff required to treat wounds, lower material cost per treatment, and shortened term of treatment required for full recovery
Simple, convenient application available in single-use foil packets - Catrix Wound Dressing is sprinkled directly from the packet onto the wound - makes it ideal for use in hospitals, extended care facilities and at-home care
Catrix Wound Dressing is packaged in cartons of 14 and 7, one-gram foil packets.
SUMMARY
Now is the time to buy shares of Lescarden (LCAR) BEFORE it gets acquired by a Smith and Nephew.
LCAR is ridiculously undervalued having an FDA and EU approved, patented and commercialized WOUND CARE product that is incredibly effective!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |